Exact Mass: 387.0106
Exact Mass Matches: 387.0106
Found 74 metabolites which its exact mass value is equals to given mass value 387.0106,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Thifensulfuron-methyl
CONFIDENCE standard compound; EAWAG_UCHEM_ID 124 CONFIDENCE standard compound; INTERNAL_ID 3688
dCDP
dCDP is a substrate for Uridine-cytidine kinase 1, Nucleoside diphosphate kinase (mitochondrial), Nucleoside diphosphate kinase homolog 5, Ribonucleoside-diphosphate reductase large subunit, Nucleoside diphosphate kinase A, Nucleoside diphosphate kinase 7, Ribonucleoside-diphosphate reductase M2 chain, Nucleoside diphosphate kinase B, Nucleoside diphosphate kinase 3, Nucleoside diphosphate kinase 6 and UMP-CMP kinase. [HMDB]. dCDP is found in many foods, some of which are oil palm, sweet bay, garden onion (variety), and italian sweet red pepper. dCDP is a substrate for Uridine-cytidine kinase 1, Nucleoside diphosphate kinase (mitochondrial), Nucleoside diphosphate kinase homolog 5, Ribonucleoside-diphosphate reductase large subunit, Nucleoside diphosphate kinase A, Nucleoside diphosphate kinase 7, Ribonucleoside-diphosphate reductase M2 chain, Nucleoside diphosphate kinase B, Nucleoside diphosphate kinase 3, Nucleoside diphosphate kinase 6 and UMP-CMP kinase. Acquisition and generation of the data is financially supported in part by CREST/JST.
benzylhydrochlorothiazide
C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic > C49185 - Thiazide Diuretic Same as: D01246
5'-Hydroxylornoxicam
5-Hydroxylornoxicam is a metabolite of Tenoxicam. 5-hydroxylornoxicam belongs to the family of Thienothiazines. These are heterocyclic compounds containing a thiophene ring fused to a thiazine.
3',4'-Dichlorobenzamil
2-Amino-5-[[1-[carboxymethyl(sulfo)amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid
2-{2-[3,5-Bis(trifluoromethyl)phenyl]hydrazono}-2-(propylsulfonyl)acetonitrile
glutathioselenol
A glutathione derivative that is glutathione in which the hydrogen attached to the sulfur is replaced by a selenol group.
5-Hydroxylornoxicam
Thiazolidine, 3-[(2,5-dichlorophenyl)sulfonyl]-2-(4-methylphenyl)- (9CI)
Thiazolidine, 2-(4-methylphenyl)-3-[[3-(trifluoromethyl)phenyl]sulfonyl]- (9CI)
5-bromo-3-[5-(morpholin-4-ylmethyl)-1H-pyridin-2-ylidene]-1H-indol-2-one
Thiazolidine, 3-[(3,4-dichlorophenyl)sulfonyl]-2-(4-methylphenyl)- (9CI)
6-BROMO-2-(2,4-DIMETHOXYPHENYL)QUINOLINE-4-CARBOXYLICACID
Benzenesulfonamide,N-(2,4-dinitro-1-naphthalenyl)-4-methyl-
3-BOC-2-(4-BROMO-PHENYL)-THIAZOLIDINE-4-CARBOXYLIC ACID
Ethylenediaminetetraacetate-copper-ammonia complex
3-Bromo-N,N-dipropyl-5-(trifluoromethyl)benzenesulfonamide
2-CYANO-N-CYCLOPROPYL-N-((2-FLUORO-4-IODOPHENYL)CARBAMOYL)ACETAMIDE
6-amino-3-cyclopropyl-1-(2-fluoro-4-iodophenyl)pyrimidine-2,4(1H,3H)-dione
ISOPROPYL (2-IODO-4-METHYL-5-(TRIFLUOROMETHYL)PHENYL)CARBAMATE
7,8-Dimethoxy-3-(3-iodopropyl)-1,3-dihydro-2H-3-benzazepin-2-one
Benzenesulfonylchloride, 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]-
tert-butyl 2-amino-5-iodo-4-(trifluoromethyl)benzoate
O-[3-chloro-4-(diethylsulfamoyl)phenyl] O,O-dimethyl phosphorothioate
4-[4-Bromo-3-[[(tetrahydro-2H-pyran-2-yl)oxy]methyl]phenoxy]benzonitrile
(4-chlorophenyl)-(3-methyl-1,3-benzothiazol-3-ium-2-yl)diazene,perchlorate
Bromotris(dimethylamino)phosphonium hexafluorophosphate
3-Bromo-N-hexyl-5-(trifluoromethyl)benzenesulfonamide
2,4-dichloro-N-[5-(5,6,7,8-tetrahydronaphthalen-2-yl)-1,3,4-oxadiazol-2-yl]benzamide
5-(1H-benzimidazol-2-ylmethylidene)-3-(2-naphthalenyl)-2-sulfanylidene-4-thiazolidinone
2,3-Dihydroxybutanedioic acid--3-(5-nitrofuran-2-yl)-5,6-dihydroimidazo[2,1-b][1,3]thiazole (1/1)
[(2R,3S,4R,5S)-5-(2-amino-5-cyano-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
N-(4-bromo-2-methylphenyl)-3-(1,3-dioxo-2-pyrrolo[3,4-c]pyridinyl)propanamide
3,5-diamino-N-[amino-[(2,4-dichlorophenyl)methylimino]methyl]-6-chloro-2-pyrazinecarboxamide
2-[(2,4-dichlorophenoxy)acetyl]-N-(4-fluorophenyl)hydrazinecarbothioamide
N-{3-[3-(5-bromo-2-methoxyphenyl)acryloyl]phenyl}propanamide
[(3aR,4R,9bR)-8-bromo-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-(2-pyridinyl)methanone
[(3aS,4S,9bS)-8-bromo-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-(2-pyridinyl)methanone
[(3aR,4S,9bR)-8-bromo-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-(2-pyridinyl)methanone
[(3aS,4R,9bS)-8-bromo-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-1-yl]-(2-pyridinyl)methanone
[5-(2-amino-5-carbamoyl-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-7-yl)-3-hydroxy-2,5-dihydrofuran-2-yl]methyl dihydrogen phosphate
Deoxycytidine diphosphate
A 2-deoxycytidine phosphate that is the 2- deoxy derivative of cytidine 5-diphosphate (CDP).
CCMI
CCMI (AVL-3288) is a potent and selective α7 nAChR-positive allosteric modulator, does not bind to or activate α7 nAChRs via the orthosteric site, and causes significant positive modulation of agonist-induced currents at α7 nAChRs. CCMI has potential in CNS diseases with cognitive dysfunction[1].
ERK5-IN-2
ERK5-IN-2 is an orally active, sub-micromolar, selective ERK5 inhibitor with IC50s of 0.82 μM, 3 μM for ERK5 and ERK5 MEF2D, respectively. ERK5-IN-2 does not interact with the BRD4 bromodomain. ERK5-IN-2 suppresses both tumor xenograft growth and basic fibroblast growth factor (bFGF) driven Matrigel plug angiogenesis[1].
